Floatz Rating
B58/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07551778CT.gov Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07549399CT.gov SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC | — | Not Yet Recruiting | — | — | — |
NCT07397338CT.gov Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | — | Recruiting | — | — | — |
NCT07349537CT.gov Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | — | Recruiting | — | — | — |
NCT07252739CT.gov KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) | — | Recruiting | — | — | — |
NCT07247110CT.gov A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) | — | Recruiting | — | — | — |
NCT07209111CT.gov A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) | — | Recruiting | — | — | — |
NCT06943820CT.gov AK129 Combination Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06915142CT.gov A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour | — | Recruiting | — | — | — |
NCT06908031CT.gov SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer | — | Recruiting | — | — | — |
Show 32 more trialsShow fewer
NCT06764771CT.gov A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | — | Recruiting | — | — | — |
NCT06835569CT.gov A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | — | Recruiting | — | — | — |
NCT06715124CT.gov QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations | — | Active Not Recruiting | — | — | — |
NCT06607185CT.gov A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06274437CT.gov A Study of BND-35 in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT06428500CT.gov QTX3046 in Patients With KRAS G12D Mutations | — | Active Not Recruiting | — | — | — |
NCT06332170CT.gov ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06241456CT.gov FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06024174CT.gov A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors | — | Terminated | — | — | — |
NCT05836324CT.gov A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05067283CT.gov A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | — | Recruiting | — | — | — |
NCT05002270CT.gov JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | — | Completed | — | — | — |
NCT04717375CT.gov Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04464967CT.gov Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | — | Withdrawn | — | — | — |
NCT04474470CT.gov A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | — | Completed | — | — | — |
NCT04449874CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | — | Active Not Recruiting | — | — | — |
NCT04485013CT.gov TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | — | Recruiting | — | — | — |
NCT04349267CT.gov Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04165031CT.gov A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | — | Terminated | — | — | — |
NCT03785249CT.gov Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | — | Active Not Recruiting | — | — | — |
NCT03319459CT.gov FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02857270CT.gov A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | — | Completed | — | — | — |
NCT02671435CT.gov A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02318901CT.gov Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | — | Terminated | — | — | — |
NCT02095054CT.gov Regorafenib and Cetuximab in Patients With Advanced Malignancy | — | Completed | — | — | — |
NCT01552434CT.gov Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | — | Terminated | — | — | — |
NCT01472016CT.gov Study of ABT-700 in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01178411CT.gov An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols | — | Completed | — | — | — |
NCT00980239CT.gov HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver | — | Completed | — | — | — |
NCT00698841CT.gov Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors | — | Completed | — | — | — |
NCT00388427CT.gov Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies | — | Completed | — | — | — |
NCT00110357CT.gov Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cetuximab (this asset) | National Cancer Institute (NCI) | P3 | B · 58 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Cetuximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Adenocarcinoma | — | P3 | BB · 70 |
| Rectal Carcinoma | — | P2 | BB · 69 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cetuximab in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cetuximab-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →